Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Recent evidence suggests that inhibition of bromodomain and extra-terminal (BET) epigenetic readers may have clinical utility against acute myeloid leukemia (AML). Here we validate this hypothesis, demonstrating the efficacy of the BET inhibitor I-BET151 across a variety of AML subtypes driven by disparate mutations. We demonstrate that a common 'core' transcriptional program, which is HOX gene independent, is downregulated in AML and underlies sensitivity to I-BET treatment. This program is enriched for genes that contain 'super-enhancers', recently described regulatory elements postulated to control key oncogenic driver genes. Moreover, our program can independently classify AML patients into distinct cytogenetic and molecular subgroups, suggesting that it contains biomarkers of sensitivity and response. We focus AML with mutations of the Nucleophosmin gene (NPM1) and show evidence to suggest that wild-type NPM1 has an inhibitory influence on BRD4 that is relieved upon NPM1c mutation and cytosplasmic dislocation. This leads to the upregulation of the core transcriptional program facilitating leukemia development. This program is abrogated by I-BET therapy and by nuclear restoration of NPM1. Finally, we demonstrate the efficacy of I-BET151 in a unique murine model and in primary patient samples of NPM1c AML. Taken together, our data support the use of BET inhibitors in clinical trials in AML.

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.

The Lim Domain Only 2 (LMO2) leukaemia oncogene encodes an LIM domain transcriptional cofactor required for early haematopoiesis. During embryogenesis, LMO2 is also expressed in developing tail and limb buds, an expression pattern we now show to be recapitulated in transgenic mice by an enhancer in LMO2 intron 4. Limb bud expression depended on a cluster of HOX binding sites, while posterior tail expression required the HOX sites and two E-boxes. Given the importance of both LMO2 and HOX genes in acute leukaemias, we further demonstrated that the regulatory hierarchy of HOX control of LMO2 is activated in leukaemia mouse models as well as in patient samples. Moreover, Lmo2 knock-down impaired the growth of leukaemic cells, and high LMO2 expression at diagnosis correlated with poor survival in cytogenetically normal AML patients. Taken together, these results establish a regulatory hierarchy of HOX control of LMO2 in normal development, which can be resurrected during leukaemia development. Redeployment of embryonic regulatory hierarchies in an aberrant context is likely to be relevant in human pathologies beyond the specific example of ectopic activation of LMO2.

Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.

Advances in sequencing technologies are giving unprecedented insights into the spectrum of somatic mutations underlying acute myeloid leukaemia with a normal karyotype (AML-NK). It is clear that the prognosis of individual patients is strongly influenced by the combination of mutations in their leukaemia and that many leukaemias are composed of multiple subclones, with differential susceptibilities to treatment. Here, we describe a method, employing targeted capture coupled with next-generation sequencing and tailored bioinformatic analysis, for the simultaneous study of 24 genes recurrently mutated in AML-NK. Mutational analysis was performed using open source software and an in-house script (Mutation Identification and Analysis Software), which identified dominant clone mutations with 100% specificity. In each of seven cases of AML-NK studied, we identified and verified mutations in 2-4 genes in the main leukaemic clone. Additionally, high sequencing depth enabled us to identify putative subclonal mutations and detect leukaemia-specific mutations in DNA from remission marrow. Finally, we used normalised read depths to detect copy number changes and identified and subsequently verified a tandem duplication of exons 2-9 of MLL and at least one deletion involving PTEN. This methodology reliably detects sequence and copy number mutations, and can thus greatly facilitate the classification, clinical research, diagnosis and management of AML-NK.

Entonox as a sedative for bone marrow aspiration and biopsy.

Bone marrow aspiration and biopsy can be a painful procedure. Sedation techniques may make this investigation more acceptable to patients, but have the potential to cause life-threatening complications, as well as requiring additional staff and equipment for safe administration. We assessed the use of Entonox, a 50 : 50 mix of nitrous oxide and oxygen, as a sedation and analgesic agent, and compared it to previous experience with the intravenous (i.v.) benzodiazepine midazolam. Patients' perception of pain, and both the operator and patient's views on the ease of the procedure and safety factors were recorded. Twenty-two patients who had previously required i.v. midazolam sedation (16), or who requested sedation (6) were studied. Fifteen of 16 (94%) found Entonox better or equal to midazolam, and only one patient (6%) found it worse. There were no serious adverse events due to Entonox. We have shown, in this small group of patients, that Entonox is an effective, safe alternative to intravenous midazolam for sedation during bone marrow biopsy, and is considered acceptable by both patients and staff. It has the major advantage that no additional staff or facilities are required for safe administration or monitoring the patient during or after the procedure.

Primary and isolated anaplastic large cell lymphoma of the bone marrow.

Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma in which the majority of patients present with advanced stage III or IV disease. Here we report a case of ALCL where bone marrow was the only site of disease, in a 60-year-old man with pyrexia and pancytopenia. The diagnosis of ALCL was made on detection of CD30-positive anaplastic cells in the bone marrow, together with prominent hemophagocytosis. Genetics confirmed the clonal nature of the disease and showed it to be anaplastic lymphoma kinase (ALK) negative. Primary isolated bone marrow ALCL should be considered in the diagnosis of pancytopenia associated with hemophagocytosis.

Effects of fast-acting high-frequency compression on the intelligibility of speech in steady and fluctuating background sounds.

This study examines whether speech intelligibility in background sounds can be improved for persons with loudness recruitment by the use of fast-acting compression applied at high frequencies, when the overall level of the sounds is held constant by means of a slow-acting automatic gain control (AGC) system and when appropriate frequency-response shaping is applied. Two types of fast-acting compression were used in the high-frequency channel of a two-channel system: a compression limiter with a 10:1 compression ratio and with a compression threshold about 9 dB below the peak level of the signal in the high-frequency channel; and a wide dynamic range compressor with a 2:1 compression ratio and with the compression threshold about 24 dB below the peak level of the signal in the high-frequency channel. A condition with linear processing in the high-frequency channel was also used. Speech reception thresholds (SRTs) were measured for two background sounds: a steady speech-shaped noise and a single male talker. All subjects had moderate-to-severe sensorineural hearing loss. Three different types of speech material were used: the adaptive sentence lists (ASL), the Bamford-Kowal-Bench (BKB) sentence lists and the Boothroyd word lists. For the steady background noise, the compression generally led to poorer performance than for the linear condition, although the deleterious effect was only significant for the 10:1 compression ratio. For the background of a single talker, the compression had no significant effect except for the ASL sentences, where the 10:1 compression gave significantly better performance than the linear condition. Overall, the results did not show any clear benefits of the fast-acting compression, possibly because the slow-acting AGC allowed the use of gains in the linear condition that were markedly higher than would normally be used with linear hearing aids.

Dependence of acyl chain packing of phospholipids on the head group and acyl chain length.

The temperature dependencies of the factor group splitting of the infrared-active CH2-scissoring bands of a series of fully hydrated gel phase diacyl phospholipids were determined. It is shown that, in all cases, the acyl chains are packed in an orthorhombic subcell and that the degree of rigidity of the subcell increases with increasing chain length. It is also demonstrated that the subcell in 3-sn-phosphatidylcholines differs from that found in 3-sn-phosphatidylethanolamines and 3-phosphatidic acids.

The gel phase of dipalmitoyl phosphatidylcholine. An infrared characterization of the acyl chain packing.

It is shown, by infrared spectroscopy, that the packing in the gel phase of fully-hydrated dipalmitoyl phosphatidylcholine is not uniform over a large temperature range. With decreasing temperature, starting at that of the pretransition, there is a gradual change in the molecular packing of the acyl chains, from near hexagonal to orthorhombic of monoclinic.